Full Press Release Details
Investigation of Sinovac
BEIJING, August 20, 2018 /PRNewswire/
-- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical
products in China, today announced that the U.S. Securities and Exchange Commission ("SEC") has concluded its investigation
into possible violations of the federal securities laws related to allegations that certain Sinovac employees made improper payments
to Chinese government officials. The SEC determined that it will not recommend or pursue an enforcement action against Sinovac
at this time. Sinovac is committed to conducting business in compliance with all applicable laws and cooperated fully with the
SEC. Sinovac will continue in its mission of researching, developing, manufacturing and commercializing vaccines that protect against
human infectious diseases.
Sinovac Biotech Ltd. is a China-based biopharmaceutical Company
that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza,
H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. Healive, the hepatitis A vaccine manufactured by the
Company has passed the assessment under WHO Prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed
by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first
company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination
campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government
stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while
also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in
Asia and South America. For more information please refer to the Company's website at www.sinovacbio.com.
Safe Harbor Statement
This announcement may include certain statements that are not
descriptions of historical facts, but are forward-looking statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by
terminology such as "will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates" and similar statements. Forward-looking statements involve risks, uncertainties and
other factors that could cause actual results to differ materially from those contained in any such statements.
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Tel: +1-646-308-1707
Email: william.zima@icrinc.com
Tel: +1-415-745-3294
Email: sbe@abmac.com
China Media Contact:
Tel: +86-10-6583-7510
Email: Edmond.Lococo@icrinc.com